AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02718846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meniace
Description: 6 mg of Meniace tablets were administered 3 times per day after meals
Study NCT02718846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isobide
Description: an initial dosage of 90 mL of Isobide solution was administered orally 3 times a day after meals
Study NCT01938170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist
Description: Subjects receiving Flumist vaccine
Study NCT01595204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic laparoscopy
Description: Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.~After the introduction of the trocar and the optic, pneumoperitoneum is induced and one or two ancillary trocars are inserted in the iliac fossae bilaterally or where it is possible. A careful complete abdominal and pelvic inspection is carried out in order to identify any possible cause of non optimal cytoreduction. All peritoneal surfaces and the gutters are closely examined and the liver is evaluated by rotating the laparoscope 360° through the umbilical port using grasping forceps as retractors. The small bowel loops and mesentery are evaluated by carefully folding back the various intestinal segments. The pelvis is explored after the bowel loops are retracted in the upper abdomen when possible. At the end of laparoscopy, a PI value is elaborated, based on table given to participant centers.
Study NCT02293681 — intervention group
Intervention type: DRUG
Intervention: Infliximab
Description: This is an observational study. Participants receiving intravenous infusion of infliximab will be observed.
Study NCT02293681 — intervention group
Intervention type: DRUG
Intervention: NSAIDs
Description: This is an observational study. Participants receiving aspirin, ibuprofen and naproxen as NSAIDs will be observed.
Study NCT02293681 — intervention group
Intervention type: DRUG
Intervention: DMARDs
Description: This is an observational study. Participants receiving methotrexate (MTX), sulfasalazine, and thalidomide as DMRADs will be observed.
Study NCT05018338 — intervention group
Intervention type: DEVICE
Intervention: Brain shift monitoring
Description: For use to monitor brain shift during craniotomy
Study NCT02439385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin/FOLFIRI
Description: Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.
Study NCT02439385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Dietary supplement of nanostructured lipid curcumin particle 100mg po bid daily
Study NCT02281058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: self-injected subcutaneous biologic medication
Study NCT03065530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Drug: Normal saline control group receive NS after delivery. Drug: butorphanol tartrate PCA: butorphanol tartrate after cesarean section.
Study NCT03065530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.03ug/kg/h
Description: Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.03ug/kg/h Dexmedetomidine after cesarean section.
Study NCT03065530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.05ug/kg/h
Description: Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.05ug/kg/h Dexmedetomidine after cesarean section.
Study NCT03065530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.08ug/kg/h
Description: Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.08ug/kg/h Dexmedetomidine after cesarean section.
Study NCT03879590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxophylline
Description: Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
Study NCT03879590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxophylline
Description: Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
Study NCT03879590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
Study NCT03879590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Both groups will receive doxophylline one group will maintain the ICS dose and the other group will receive a reduced ICS dose (Maintaining the same GINA treatment step). After 4 weeks both groups will interchange treatment scheme.
Study NCT03205969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional mobile game
Description: Functional mobile game for chemotherapy side effect education
Study NCT02723630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib 10 mg
Description: Treatment 1: low Type-C crystal level \<12%~Treatment 2: reference\* Type-C crystal level 12% to 26%~Treatment 3: high Type-C crystal level >26%
Study NCT01524289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anacetrapib
Description: One oral tablet, orally once daily for 52 weeks
Study NCT01619904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Following standard protocol during peri-operative period
Study NCT00680277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: spirulina ß-carotene
Description: an acute dose of spirulina up to 5 g
Study NCT00680277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: spirulina ß-carotene
Description: vitamin A value of spirulina ß-carotene
Study NCT02348281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 150mg, po, qd, d1-28
Study NCT02069535 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVANZ Cupressus
Description: AVANZ Cupressus
Study NCT01246258 — intervention group
Intervention type: OTHER
Intervention: Vestibular evoked myogenic potentials (VEMPs)
Description: Standard test of balance function
Study NCT01246258 — intervention group
Intervention type: OTHER
Intervention: Utricular centrifugation test
Description: Standard test of balance function
Study NCT01524289 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One oral tablet once daily for 52 weeks
Study NCT02104180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urgotul
Description: sterile, hydrocolloid dressing, that consist of a polyester fabric coated with hydrocolloid particles and vaseline
Study NCT02104180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TulleGras M.S.
Description: Sterile dressing that consists of viscose tissue coated with mineral vaseline
Study NCT01906840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turmeric
Study NCT03567447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droxidopa
Description: starting with 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
Study NCT01906840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01917825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDT-15
Study NCT04596813 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb 300 mL device
Description: Intra-and postoperative CytoSorb hemoadsorption
Study NCT01581190 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bananas versus 6% carbohydrate beverage
Description: Trained cyclists (N=14) completed two 75-km cycling time trials (randomized, crossover) while ingesting BAN or CHO (0.2 g/kg carbohydrate every 15 min).
Study NCT03567447 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: appearing to be 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
Study NCT01768299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200 mg oral Mifepristone 24 hours before 400 mcg buccal misoprostol
Study NCT01768299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 200 mg oral Mifepristone simultaneously 400 mcg buccal misoprostol
Study NCT00071773 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified-ETDRS photocoagulation
Description: A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
Study NCT00071773 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mild Macular Grid photocoagulation
Description: A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
Study NCT02108730 — intervention group
Intervention type: PROCEDURE
Intervention: restrictive pancreatic resection
Description: Restrictive, spleen-preserving resection of the pancreatic tail by laparoscopy
Study NCT03567447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: appearing to be 100 mg TID and increasing in 100 mg TID increments, to a maximum of 600mg TID, to identify the highest tolerated dose for each patient.
Study NCT03385356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D supplementation of 1000IU vs 4000IU vitamin D per day for four months during winter time, when levels of vitamin D in serum of MS patients are especially low.
Study NCT04205422 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BIPAP
Description: Biphasic Intermittent Positive Airway Pressure
Study NCT04205422 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: APRV
Description: Airway Pressure Release Ventilation
Study NCT03077295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fibre
Description: High fibre/carbohydrate (50% CHO, 35% fat and 15% Protein) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Total dietary fibre will be at least 30g/d for 2000kcal intake and provided as a mixed soluble and insoluble fibre sources to maintain palatability of the diet (e.g. wheat bran, fava bean, lentil, buckwheat).
Study NCT03077295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein
Description: • High protein diet (30% protein, 35% fat and 35% CHO) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Protein will be a mixed meat matrix to include poultry, fish, red meat, prawns, eggs, dairy. Total dietary fibre will be no more than 15g/d for 2000kcal intake.
Study NCT01691482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol/salbutamol
Description: Albuterol/salbutamol (daily)
Study NCT01691482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium
Description: Ipratropium (daily)
Study NCT03811951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolin R
Description: Novolin R is a sterile, clear, aqueous, and colorless solution that contains human insulin (rDNA origin) 100 units/mL, glycerol 16 mg/mL, metacresol 3 mg/mL, zinc chloride approximately 7 mcg/mL and water for injection. The pH (potential Hydrogen) is adjusted to 7.4. Hydrochloric acid 2N (concentration) or sodium hydroxide 2N may be added to adjust pH. Novolin R vials are latex-free. The drug substance is being purchased from McKesson.
Study NCT04219267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: character strengths-based intervention
Description: Character strengths-based intervention (CSI) is one kind of positive psychology interventions. It specifically focuses on character strengths, related activities and exercises assisting individuals to reconnect with their characters and promote self-conceptualization.~The researcher will develop an education module on CSI based on the previous literatures conducted in China and other countries. Before the RCT, this module will be adapted to Chinese participants. During the intervention, participants in the intervention group will be offered the educational module to learn about strengths, comments around the definition of character strengths and examples of specific strengths.
Study NCT04219267 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: early memories
Description: In early memories, participants will be instructed to write down something from their early memories every day. The memories could be the things happened several days or many years before the writing day. The memories could be participant' travel experiences or food for a day. There are no strict restrictions on the timing or content of these early events.
Study NCT01943695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Study NCT01943695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Information
Description: Subjects will be given material regarding cancer and it's impact.
Study NCT01943695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised Home Based Training
Description: Patients that elect supervised home based training platform or plan to complete unsupervised training sessions will receive a study kit which includes a heart rate monitor, blood pressure cuff, treadmill and tablet to complete aerobic training requirements. The study kit will be given to the patient upon completion of their baseline testing. The treadmill will be shipped to the patient's home and coordinated by the Ex Onc group. The treadmills are MSK owned equipment that will be deployed to the patient's homes via the vendor TechnoGym. A member of Ex Onc will provide an orientation session for the patient to set up all study kit items. If there is a delay in the patient receiving the treadmill , or any other unforeseen circumstance, patients may be assigned a temporary unsupervised training program until the treadmill is delivered.
Study NCT00431041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin
Description: Oral
Study NCT00431041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxybutynin immediate release
Description: Oral
Study NCT01165450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexagon
Description: There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
Study NCT01165450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle only
Description: There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
Study NCT00789386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil (Ultiva ®; Glaxo-Smith-Kline; Vienna, Austria) at an initial dose of 0.24 µg kg-1 min-1 will be applied iv during 60 minutes.
Study NCT00789386 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied iv as active placebo at a dose of 7.5 µg.kg-1.min-1 over 10 minutes to mimic typical central nervous side effects of remifentanil.
Study NCT03033810 — intervention group
Intervention type: DEVICE
Intervention: Fractional flow reserve and instantaneous wave-free ratio
Description: 1. To explain discrepancies between FFR and iFR using demographic, morphological, genetic and functional indices.~2. The development of software for the automatic detection of the lowest point of microvascular resistance.
Study NCT02450539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT02450539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Administered IV
Study NCT02597374 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG
Description: A 45 mn EEG will be performed in each participants during action and action observation of each hand.
Study NCT01215279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: 100 mg oral treatment once daily for 28 days
Study NCT01215279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to AZD2423
Description: Oral treatment once daily for 28 days
Study NCT01576705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thyroid hormone and folinic acid
Description: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules
Study NCT01576705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thyroid hormone and folinic acid
Description: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules
Study NCT01576705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: thyroid hormone and folinic acid
Description: thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules
Study NCT02421653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNP90
Description: 90 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
Study NCT02421653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MNP45
Description: 45 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
Study NCT02421653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IODISED OIL
Description: 200 mg iodine oil capsule; oral route; once at study start
Study NCT00096408 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Abdominal Hysterectomy
Description: For patients with clinical stage I disease, removal of the uterus and both tubes and ovaries are considered current standard treatment in Australia.
Study NCT00096408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy
Description: The technique of total laparoscopic hysterectomy (TLH), utilising the McCartney tube, has been developed by Anthony J. McCartney over the last 10 years. It allows the completion of the hysterectomy entirely laparoscopically, without the need for additional vaginal surgery.
Study NCT03539796 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional epidurals (EPI)
Description: Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. The catheter will be inserted 3-5cm in the epidural space. A test dose with 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine in 5mL increments until a T4 dermatome level is reached. Epidural fentanyl 100mcg will be administered during initial dosing, and morphine-preservative free (PF) 3mg will be given via epidural after delivery of the fetus.
Study NCT03539796 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined-spinal epidural technique (CSE)
Description: Using the Arrow Epidural Kit (AK-05560) an epidural will be placed using the LOR to saline or air technique. A 26g Gertie Marx needle will be inserted through the Touhy epidural needle and used to puncture the dura; clear, free flowing CSF will return in the needle and 12mg bupivacaine, 10mcg fentanyl, 200mcg morphine-PF. The 26g spinal needle will be removed, and the epidural catheter inserted through the epidural needle 3-5cm in the epidural space. No epidural test dose will be given immediately compared to the above procedures secondary to intrathecal injection of local anesthetic with this CSE technique. Only after approximately 1 hour after intrathecal injection will a test dose of 3mL 1.5% Lidocaine with 1:200,000 epinephrine will be used to confirm the absence of intrathecal or intravascular catheter placement. The epidural catheter will then be dosed with 0.5% Bupivacaine for the remainder of the procedure if necessary.
Study NCT04431089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHC014748M
Description: Each treatment cycle is comprised of 28-day consecutive dosing of SHC014748M, 200mg QD (Days 1 to28). Upon completion of each cycle, patients may continue to receive oral SHC014748M if they can benefit from the treatment and the toxicity is tolerable.
Study NCT01894815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram oxalate
Description: The investigators will use 10mg and 20mg pills. The investigators will up-titrate escitalopram from 10 to 20mg/day according to the patient tolerability. The maximum dose (20mg/day) is sought to be achieved at week 3.